fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

(ignored: NYSTATIN)

Metronidazole was listed in the December 27, 2023 extract; the same DIN 00545066 is listed as Apo-Metronidazole Tablets in the current extract (September 22, 2026). This is not an absent DIN. Source: odb-formulary-ed43-extract-2023-12-27.xml; odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Apo-metronidazole tablets (metronidazole) and other metronidazole products

Metronidazole

Form:

15 of 15 products shown

11 general benefit · 4 not a benefit

Apo-Metronidazole Tablets · DIN 00545066 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Metronidazole Tablets · DIN 00545066 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.1716 Health Canada: Marketed since 2024-05-22 · brand APO-METRONIDAZOLE TABLETS · ATC P01AB01 METRONIDAZOLE · form Tablet · route Oral · ingredients METRONIDAZOLE 250 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Metronidazole Tablets: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0572). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00545066)

Source record
DIN 00545066: Apo-Metronidazole Tablets Raw flags: sec3=Y Item: 083200001; group id 125; item number 0210; lccId None; manufacturer id APX Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.0572; ministry $0.0572 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00545066 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4902
Interchangeable products
Flagyl · DIN 01926896 · not recorded Mint-Metronidazole · DIN 02535807 · $0.0572
Shortage status: resolved shortage (ended October 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00545066
Shortage record checked October 6, 2026

Noritate · DIN 02156091 · 1% · Top Cr

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Noritate · DIN 02156091 Manufacturer: Valeant Canada Ltd.; listing date 1997-04-10 Health Canada: Marketed since 2019-05-07 · brand NORITATE · ATC D06BX01 METRONIDAZOLE · form Cream · route Topical · ingredients METRONIDAZOLE 1 %/W/W · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Noritate: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8149). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02156091)

Source record
DIN 02156091: Noritate Raw flags: sec3=Y Item: 840416037; group id 830; item number 2019; lccId None; manufacturer id VAL Source form: Top Cr; strength: 1% Recorded listing: General benefit Source prices (unrounded): $0.8149; ministry $0.8149 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02156091 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19257
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02156091
Shortage record checked October 6, 2026

Metrogel · DIN 02297809 · 1% · Top Gel

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Metrogel · DIN 02297809 Manufacturer: Galderma Canada Inc; listing date 2010-03-02 Health Canada: Marketed since 2007-12-20 · brand METROGEL 1% · ATC D06BX01 METRONIDAZOLE · form Gel · route Topical · ingredients METRONIDAZOLE 1 % · company Galderma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Metrogel: Formulary list price $0.72 per unit (the source does not state the unit; exact figure $0.7235). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02297809)

Source record
DIN 02297809: Metrogel Raw flags: sec3=Y Item: 840416043; group id 830; item number 2021; lccId None; manufacturer id GAC Source form: Top Gel; strength: 1% Recorded listing: General benefit Source prices (unrounded): $0.7235; ministry $0.7235 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02297809 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78314
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297809
Shortage record checked October 6, 2026

Mint-Metronidazole · DIN 02535807 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Metronidazole · DIN 02535807 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-10-31 Daily cost (source): $0.1716 Health Canada: Marketed since 2023-09-07 · brand MINT-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Tablet · route Oral · ingredients METRONIDAZOLE 250 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Metronidazole: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0572). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02535807)

Source record
DIN 02535807: Mint-Metronidazole Raw flags: sec3=Y Item: 083200001; group id 125; item number 0210; lccId None; manufacturer id MIN Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.0572; ministry $0.0572 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02535807 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102463
Interchangeable products
Apo-Metronidazole Tablets · DIN 00545066 · $0.0572 Flagyl · DIN 01926896 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535807
Shortage record checked October 6, 2026

Apo-Metronidazole · DIN 02248562 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Metronidazole · DIN 02248562 Manufacturer: Apotex Inc.; listing date 2004-07-20 Daily cost (source): $0.8217 Health Canada: Marketed since 2018-04-26 · brand APO-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248562)

Source record
DIN 02248562: Apo-Metronidazole Raw flags: sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id APX Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.2739; ministry $0.2739 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248562 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72917
Interchangeable products
Auro-Metronidazole · DIN 02470284 · $0.2739 Flagyl · DIN 01926853 · not recorded M-Metronidazole · DIN 02519755 · $0.2739 Metronidazole · DIN 02518767 · $0.2739 Metronidazole · DIN 02534592 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: shortage reported ended August 7, 2026 (report last updated August 7, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248562
Shortage record checked October 6, 2026

Auro-Metronidazole · DIN 02470284 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Metronidazole · DIN 02470284 Manufacturer: Auro Pharma Inc.; listing date 2018-07-31 Daily cost (source): $0.8217 Health Canada: Marketed since 2018-04-03 · brand AURO-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02470284)

Source record
DIN 02470284: Auro-Metronidazole Raw flags: sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id AUR Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.2739; ministry $0.2739 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02470284 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95926
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Flagyl · DIN 01926853 · not recorded M-Metronidazole · DIN 02519755 · $0.2739 Metronidazole · DIN 02518767 · $0.2739 Metronidazole · DIN 02534592 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: resolved shortage (ended June 24, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02470284
Shortage record checked October 6, 2026

M-Metronidazole · DIN 02519755 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
M-Metronidazole · DIN 02519755 Manufacturer: Mantra Pharma Inc.; listing date 2022-04-29 Daily cost (source): $0.8217 Health Canada: Marketed since 2022-03-04 · brand M-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519755)

Source record
DIN 02519755: M-Metronidazole Raw flags: sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id MAT Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.2739; ministry $0.2739 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519755 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100899
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Auro-Metronidazole · DIN 02470284 · $0.2739 Flagyl · DIN 01926853 · not recorded Metronidazole · DIN 02518767 · $0.2739 Metronidazole · DIN 02534592 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519755
Shortage record checked October 6, 2026

Metronidazole · DIN 02518767 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Metronidazole · DIN 02518767 Manufacturer: Jamp Pharma Corporation; listing date 2022-06-30 Daily cost (source): $0.8217 Health Canada: Marketed since 2022-05-19 · brand METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02518767)

Source record
DIN 02518767: Metronidazole Raw flags: sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id JPC Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.2739; ministry $0.2739 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02518767 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100806
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Auro-Metronidazole · DIN 02470284 · $0.2739 Flagyl · DIN 01926853 · not recorded M-Metronidazole · DIN 02519755 · $0.2739 Metronidazole · DIN 02534592 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02518767
Shortage record checked October 6, 2026

Metronidazole · DIN 02534592 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Metronidazole · DIN 02534592 Manufacturer: Sanis Health Inc.; listing date 2024-03-28 Daily cost (source): $0.8217 Health Canada: Marketed since 2023-12-21 · brand METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534592)

Source record
DIN 02534592: Metronidazole Raw flags: sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id SAI Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.2739; ministry $0.2739 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534592 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102350
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Auro-Metronidazole · DIN 02470284 · $0.2739 Flagyl · DIN 01926853 · not recorded M-Metronidazole · DIN 02519755 · $0.2739 Metronidazole · DIN 02518767 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534592
Shortage record checked October 6, 2026

PMS-Metronidazole · DIN 00783137 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-Metronidazole · DIN 00783137 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Daily cost (source): $0.8217 Health Canada: Marketed since 2021-04-29 · brand PMS-METRONIDAZOLE · ATC J01XD01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00783137)

Source record
DIN 00783137: PMS-Metronidazole Raw flags: sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id PMS Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.2739; ministry $0.2739 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00783137 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9910
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Auro-Metronidazole · DIN 02470284 · $0.2739 Flagyl · DIN 01926853 · not recorded M-Metronidazole · DIN 02519755 · $0.2739 Metronidazole · DIN 02518767 · $0.2739 Metronidazole · DIN 02534592 · $0.2739
Shortage status: resolved shortage (ended May 23, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00783137
Shortage record checked October 6, 2026

Metrogel · DIN 02092832 · 0.75% · Top Gel

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Metrogel · DIN 02092832 Manufacturer: Galderma Canada Inc; listing date 1996-10-01 Health Canada: Marketed since 1994-12-31 · brand METROGEL 0.75% · ATC D06BX01 METRONIDAZOLE · form Gel · route Topical · ingredients METRONIDAZOLE 0.75 % · company Galderma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Metrogel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02092832)

Source record
DIN 02092832: Metrogel Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840416036; group id 830; item number 2020; lccId None; manufacturer id GAC Source form: Top Gel; strength: 0.75% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02092832 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17824
Interchangeable products
Taro-Metronidazole Gel · DIN 02567342 · not recorded
Shortage status: resolved shortage (ended December 21, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02092832
Shortage record checked October 6, 2026

Taro-Metronidazole Gel · DIN 02567342 · 0.75% · Top Gel

Off-Formulary Interchangeable, not an ODB benefitApproved · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Taro-Metronidazole Gel · DIN 02567342 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2026-08-31 Health Canada: Approved since 2026-04-07 · brand TARO-METRONIDAZOLE GEL · ATC D06BX01 METRONIDAZOLE · form Gel · route Topical · ingredients METRONIDAZOLE 0.75 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02567342)

Source record
DIN 02567342: Taro-Metronidazole Gel Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840416036; group id 830; item number 2020; lccId None; manufacturer id TAR Source form: Top Gel; strength: 0.75% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $3.7845; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02567342 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106976
Interchangeable products
Metrogel · DIN 02092832 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02567342
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since April 7, 2026 — choose a marketed DIN from the same-category list.

Flagyl · PIN 01926896 · 250 mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Flagyl · DIN 01926896 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 2001-02-28 Daily cost (source): $0.1716 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Flagyl: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 01926896)

Source record
DIN 01926896: Flagyl Raw flags: notABenefit=Y, sec3=Y Item: 083200001; group id 125; item number 0210; lccId None; manufacturer id RPP Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926896 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Apo-Metronidazole Tablets · DIN 00545066 · $0.0572 Mint-Metronidazole · DIN 02535807 · $0.0572
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926896
Shortage record checked October 6, 2026

Flagyl · DIN 01926861 · 10% · Vag Cr-App

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.Discontinued November 26, 2024 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Flagyl · DIN 01926861 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2024-11-26 · brand FLAGYL · ATC G01AF01 METRONIDAZOLE · form Cream · route Vaginal · ingredients METRONIDAZOLE 10 % · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Flagyl: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2740). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926861)

Source record
DIN 01926861: Flagyl Raw flags: sec3=Y Item: 840416004; group id 830; item number 2022; lccId None; manufacturer id SAV Source form: Vag Cr-App; strength: 10% Recorded listing: General benefit Source prices (unrounded): $0.2740; ministry $0.2740 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926861 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12997
Shortage status: discontinued (November 19, 2024, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926861
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 26, 2024 — choose a marketed DIN from the same-category list.

Flagyl · DIN 01926853 · 500 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.Discontinued May 15, 2024 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Flagyl · DIN 01926853 Manufacturer: Sanofi-Aventis Canada Inc.; listing date 1996-10-01 Daily cost (source): $0.8217 Health Canada: Cancelled pre market since 2024-05-15 · brand FLAGYL · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Flagyl: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926853)

Source record
DIN 01926853: Flagyl Raw flags: notABenefit=Y, sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id SAC Source form: Cap; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926853 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12221
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Auro-Metronidazole · DIN 02470284 · $0.2739 M-Metronidazole · DIN 02519755 · $0.2739 Metronidazole · DIN 02518767 · $0.2739 Metronidazole · DIN 02534592 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: discontinued (January 31, 2023, reported by ODAN LABORATORIES LTD); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926853
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled pre market since May 15, 2024 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D06B, G01A): coverage varies; not interchangeable

  • Metronidazole + nystatin (Flagystatin): general benefit
  • Silver sulfadiazine (Flamazine): general benefit
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:32 Trichomonacides) and how they are covered

No products matched this class search: “08:32”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives

Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered

Matched class: 84:04:16 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: METRONIDAZOLE & NYSTATIN, SILVER SULFADIAZINE 84:04:16 Other Anti-Infectives

METRONIDAZOLE & NYSTATIN

· 2 products · General benefit · strengths: 500mg & 100000U/g, 500mg & 100000U · Vag Cr-App, Vag Sup

SILVER SULFADIAZINE

· 2 products · General benefit · strengths: 1% · Cr, Cr-50g Pk

POVIDONE - IODINE

· 2 products · Listed, not a benefit · strengths: 10% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:16
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:08 Fungicides, 84:04:12 Parasiticides Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-METRONIDAZOLE TABLETS (Metronidazole Tablets) is indicated for: Bacterial Vaginosis Metronidazole is indicated for the treatment of bacterial vaginosis. Protozoal Infections • Trichomonal infections in men as well as in women (protozoal infection caused by Trichomonas vaginalis). • Hepatic and intestinal amebiasis. • Giardiasis. Bacterial Infections Treatment: Culture and susceptibility studies should be performed to determine the causative organisms and their susceptibility to metronidazole. Based on clinical judgment and anticipated bacteriological findings, therapy may be started while awaiting the results of these tests. However, modification of the treatment may be necessary once these results become available. In mixed aerobic and anaerobic infections, consideration should be given to the concomitant administration of an antibiotic appropriate for the treatment of the aerobic component of the infection. See 7 Warnings and Precautions, General. Metronidazole has also been used in the treatment of a small number of cases of brain or lung infections (some with abscesses) caused by anaerobic bacteria. Prophylaxis: If there are signs of infections, spe… https://pdf.hres.ca/dpd_pm/00084527.PDF PM date: 2026-04-20 Source product: APO-METRONIDAZOLE TABLETS; DIN 00545066; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Metronidazole · DIN 02248562 Shortage status: shortage reported ended 2026-08-07 (report last updated 2026-08-07); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248562

Check this DIN again

Flagyl · DIN 01926861 Shortage status: discontinued (2024-11-19, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926861

Check this DIN again

Flagyl · DIN 01926853 Shortage status: discontinued (2023-01-31, reported by ODAN LABORATORIES LTD); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926853

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Metrogel, Taro-Metronidazole Gel, Flagyl: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026